World Allergy Organization Journal最新文献

{"title":"Clinical profile, prevalence, and burden of chronic spontaneous urticaria in the United States","authors":"Weily Soong MD ,&nbsp;Dhaval Patil MS ,&nbsp;Jonathan Rodrigues MD ,&nbsp;Ravneet K. Kohli M. Pharm ,&nbsp;Kathryn Krupsky PhD ,&nbsp;Shaloo Gupta MS ,&nbsp;Bridget L. Balkaran MPH ,&nbsp;Maria-Magdalena Balp MD","doi":"10.1016/j.waojou.2025.101081","DOIUrl":"10.1016/j.waojou.2025.101081","url":null,"abstract":"<div><h3>Background</h3><div>Data on the prevalence and burden of chronic spontaneous urticaria (CSU) are limited in the United States (US).</div></div><div><h3>Objective</h3><div>To estimate the burden, clinical profile, and prevalence of diagnosed CSU in the United States.</div></div><div><h3>Methods</h3><div>Data from respondents with physician-diagnosed CSU were collected from the 2019 National Health and Wellness Survey (NHWS). Outcomes assessed included diagnosed CSU prevalence, demographics, clinical profile, and burden using the 36-item Short Form Survey version 2 (SF-36v2; physical and mental component summary [PCS and MCS] scores), Short-Form 6 Dimension (SF-6D) and EuroQol-5 Dimension (EQ-5D) utility scores, Dermatology Life Quality Index (DLQI), Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Work Productivity and Activity Impairment (WPAI) questionnaire, and healthcare resource utilization over the past 6 months.</div></div><div><h3>Results</h3><div>Among 74,994 respondents, 815 reported physician-diagnosed chronic urticaria, with 635 (77.9%) having CSU. The weighted prevalence (95% confidence interval) of diagnosed CSU was 0.78% (0.78%–0.78%). The mean (standard deviation [SD]) age at diagnosis was 37.0 (17.1) years, and 51.7% of respondents were female. Lower (worse) MCS and PCS scores were observed than in the overall NHWS population. The mean (SD) SF-6D and EQ-5D health utility scores were 0.54 (0.14) and 0.62 (0.34), respectively. The mean (SD) DLQI score was 13.8 (11.2), with more than 74.0% of respondents reporting anxiety (GAD-7 ≥5) and depression (PHQ-9 ≥5). Mean percent (SD) scores for absenteeism, presenteeism, overall work impairment, and activity impairment were 36.5% (26.1), 67.2% (34.9), 73.1% (34.2), and 62.6% (34.1), respectively. The percentage of patients visiting any healthcare provider, an emergency department, or requiring hospitalization was 96.5%, 60.2%, and 55.9%, respectively.</div></div><div><h3>Conclusion</h3><div>This real-world study reveals a higher prevalence of diagnosed CSU in the United States than previously reported, along with significant humanistic and economic burdens.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101081"},"PeriodicalIF":3.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk behaviours and non-atopic comorbidities of adolescents with asthma","authors":"Trine Mølbæk-Engbjerg MD ,&nbsp;Nilo Vahman MD, Ph.D. ,&nbsp;Mina Ali MSc, Ph.D. ,&nbsp;Frederikke Skov MD ,&nbsp;Rebecca Vinding MD, Ph.D. ,&nbsp;David Horner MD, Ph.D. ,&nbsp;Nicklas Brustad MD, Ph.D. ,&nbsp;Jonathan Thorsen MD, Ph.D. ,&nbsp;Ann-Marie M. Schoos MD, Ph.D., DMSc ,&nbsp;Jakob Stokholm MD, Ph.D. ,&nbsp;Klaus Bønnelykke MD, Ph.D. ,&nbsp;Bo Chawes MD, Ph.D., DMSc","doi":"10.1016/j.waojou.2025.101093","DOIUrl":"10.1016/j.waojou.2025.101093","url":null,"abstract":"<div><h3>Background</h3><div>Risk behaviours, obesity, and neuropsychiatric comorbidity have been demonstrated in various chronic diseases but are less well described among adolescents with asthma.</div></div><div><h3>Methods</h3><div>We clinically assessed asthma status at the 18-year follow-up visit of the Danish Copenhagen Prospective Studies on Asthma in Childhood (COPSAC₂₀₀₀) birth cohort born to mothers with asthma, and we investigated risk behaviours and non-atopic comorbidities. We included obesity and neuropsychiatric diseases captured from medical records and electronic questionnaires on behavioural traits and psychopathology. Associations between asthma status, risk behaviours, and non-atopic comorbidity were analysed using logistic regression models.</div></div><div><h3>Results</h3><div>A total of 370 individuals (90%) completed the 18-year visit, and 93 of these (25.1%) had current asthma. Comparing adolescents with and without asthma, binge drinking was reported in 75.2% vs 66.0%, current smoking in 26.9% vs 32.9%, and drug use in 16.1% vs 26.0%. High daily screen use was reported in 25.8% vs 16.6%; 26.9% vs 17.3% reported self-destructive behaviour; 24.7% vs 14.1% had neuropsychiatric comorbidity, and 10.8% vs 6.9% had obesity. In univariate analyses, asthma was associated with self-destructive behaviour, OR = 1.84 (1.03–3.21), p = 0.035, and neuropsychiatric comorbidity, OR = 2.01 (1.11–3.56), p = 0.019. In multivariable analysis with backward selection, asthma was associated with neuropsychiatric comorbidity, OR = 2.04 (1.004–4.12), p = 0.049, a trend of increased self-destructive behaviour, OR = 1.76 (0.93–3.29), p = 0.079, and less drug use, OR = 0.59 (0.29–0.96), p = 0.045.</div></div><div><h3>Conclusion</h3><div>Asthma was associated with neuropsychiatric comorbidity and self-destructive behaviour, but less drug use. There were no consistent associations with other risk behaviours or obesity.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101093"},"PeriodicalIF":3.9,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of the primary sensitizing mite (dominant mite) in patients with allergic respiratory disease sensitized to Dermatophagoides pteronyssinus and Lepidoglyphus destructor","authors":"José Arias-Irigoyen MD ,&nbsp;Irene Arias-Talavera MD ,&nbsp;Manuel Lombardero PhD ,&nbsp;Agustín Galán BSc ,&nbsp;Rafael I. Monsalve PhD","doi":"10.1016/j.waojou.2025.101092","DOIUrl":"10.1016/j.waojou.2025.101092","url":null,"abstract":"<div><h3>Objective</h3><div>To identify the dominant mite in patients with allergic respiratory disease (ARD) and double sensitization to <em>Dermatophagoides pteronyssinus</em> (Dpt) and <em>Lepidoglyphus destructor</em> (Ld).</div></div><div><h3>Methods</h3><div>Cross-sectional study including patients with Dpt and Ld sensitization (skin prick test [SPT] and specific IgE [sIgE]), with ARD. We measured sIgE to Dpt and Ld major allergens and performed CAP Inhibition experiments. The dominant mite was determined considering the Dpt/Ld ratio (≥5 Dpt and ≤0.2 Ld dominance) and CAP inhibition results (heterologous inhibition ≥50% indicates dominance).</div></div><div><h3>Results</h3><div>We included 67 patients (62.7% men), with a mean (range) age of 35.8 (7–81) years. We found significant correlations between sIgE to Dpt whole extract (Dpt-sIgE) and sIgE to Der p 1, Der p 2, and Der p 23 (<em>p</em> &lt; 0.0001) and between Ld-sIgE and Lep d 2-sIgE (<em>p</em> &lt; 0.0001). No significant correlation was found between SPT wheal diameter and Dpt-sIgE and Ld-sIgE, nor between Ld-sIgE or Lep d 2-sIgE and Der p 23-sIgE. Patients were classified into group A (Dpt dominance), n = 31 (46.3%); group B (Ld dominance), n = 8 (11.9%); and group C (unclear dominance), n = 28 (41.8%). A Dpt/Ld ratio ≥3 diagnosed 90.3% of patients in group A, ≤0.2 diagnosed 87.5% of patients in group B, and a ratio between 0.4 and 3 diagnosed 78% of patients in group C.</div></div><div><h3>Conclusions</h3><div>In patients with ARD sensitized to Dpt and Ld, the sIgE Dpt/Ld ratio and, in specific situations, the Der p 1+Der p 23/Ld ratio, allow identification of the dominant mite in a high percentage of cases.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101092"},"PeriodicalIF":3.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144633018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 1 interferon signalling orchestrated by gut microbiota suppresses IgE-mediated anaphylaxis associated with vitamin D3 signalling","authors":"Bangtao Chen PhD ,&nbsp;Tingting Song MD ,&nbsp;Fei Hao PhD ,&nbsp;Zhi Yang PhD ,&nbsp;Jing Yang PhD","doi":"10.1016/j.waojou.2025.101089","DOIUrl":"10.1016/j.waojou.2025.101089","url":null,"abstract":"<div><h3>Objective</h3><div>IgE/antigen (Ag)-mediated systemic anaphylaxis (SA) involves alterations in type 1 interferon (IFN1), vitamin D3(VD3) and the gut microbiota. However, their interactions remain largely unknown. This study aimed to investigate the interactions between IFN1 and VD3 signalling at steady-state and their relationships with the gut microbiota underlying SA.</div></div><div><h3>Methods</h3><div>Female adult C57BL/6 mice lacking IFN1 alpha receptor subunit 1 (<em>Ifnar1</em>, <em>Ifnar1</em>^−/−), immune-related GTPase family M protein 1 (<em>Irgm1</em>, <em>Irgm1</em>^−/−) or VD3 receptor (<em>Vdr</em>, <em>Vdr</em>^−/−) were intravenously (IV) administered with IgE/Ag to induce passive SA (PSA) or intraperitoneally (IP) administered ovalbumin (OVA) on days 1, 15, and 29, followed by IV OVA on day 43 to induce active SA (ASA). IFNα (5000 U, 2 doses) and IFNα (3500 U, 12 doses) were IP administered in PSA and ASA models, respectively. Supplementation of VD3 (VD3-rich diet for 3 weeks) or bacteria (oral administration daily for 6 weeks) was performed. The effects of IFN1 and VD3 signalling on the activation of murine bone marrow-derived mast cells (mBMMCs) were tested <em>in vitro</em>.</div></div><div><h3>Results</h3><div>Compared to wild-type (<em>Wt</em>) mice, both PSA and ASA were more severe in <em>Ifnar1</em>^−/− or <em>Vdr</em>^−/− mice (with greater severity in <em>Ifnar1</em>^−/− than in <em>Vdr</em>^−/− mice), but were significantly attenuated in <em>Irgm1</em>^−/− mice. The inhibitory effects of exogenous IFNα on PSA and OVA-IgE production were partially impaired in <em>Vdr</em>^−/− mice, while the inhibitory effects of exogenous VD3 remained intact in <em>Ifnar1</em>^−/− mice. At steady state, the serum VD3 levels decreased in <em>Ifnar1</em>^−/− and increased in <em>Irgm1</em>^−/− mice, whereas the serum IFN1 levels remained unchanged in <em>Vdr</em>^−/− mice. During IgE production, endogenous IFN1 and VD3 expressions, along with faecal <em>Alistipes</em> and <em>Bacteroides</em>, decreased. Oral supplementation with <em>Bacteroides</em> significantly inhibited IgE production via the IFN1/VD3 axis, whereas <em>Alistipes</em> moderately reduced IgE production by slightly upregulating VD3 expression independent of IFN1 modulation. Both spontaneous- and induced-degranulation were more prominent in <em>Vdr</em>^−/− than in <em>Ifnar1</em>^−/− mBMMCs. IgE/Ag stimulation led to a greater reduction in membrane IFNAR1 in <em>Vdr</em>^−/− than in <em>Wt</em> mBMMCs. Inhibition of P38 and PKD2 kinase significantly and partially rescued membrane IFNAR1 expression in <em>Vdr</em>^−/− mBMMCs, respectively. Exogenous VD3 could reverse the IFNAR1 reduction and thereby enhance IFNα-mediated anti-degranulation in <em>Wt</em> mBMMCs, an effect that was lost in <em>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101089"},"PeriodicalIF":3.9,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of IgE-mediated food allergy and its impact on child growth: A machine learning approach","authors":"Ning Zhu MMed ,&nbsp;Tingting Chen MMed ,&nbsp;Lei Wang PhD ,&nbsp;Fangyuan Cai MMed ,&nbsp;Xiaoying Zhong ,&nbsp;Xiaoxiao Fang MMed ,&nbsp;Mingxin Chen MMed ,&nbsp;Junyi Lin MMed ,&nbsp;Huixi Tu ,&nbsp;Yimin Zhao ,&nbsp;Yihan Hu Bachelor ,&nbsp;Weixi Zhang PhD ,&nbsp;Jingjing Song PhD","doi":"10.1016/j.waojou.2025.101088","DOIUrl":"10.1016/j.waojou.2025.101088","url":null,"abstract":"<div><h3>Objective</h3><div>Food allergy (FA) directly affects children's nutritional status, with a significantly higher risk of growth retardation among affected children. Identifying risk factors for FA and strategies to promote growth catch-up can offer valuable guidance for the treatment and nutritional management of children with FA.</div></div><div><h3>Design</h3><div>We developed machine learning models to predict the occurrence of immunoglobulin E-mediated food allergy (IgE-FA) and the likelihood of post-treatment growth catch-up, using demographic and biological baseline data.</div></div><div><h3>Patients</h3><div>We recruited 130 children aged 0–3 years with IgE-FA as the FA group and 65 healthy children as the control group.</div></div><div><h3>Results</h3><div>Using machine-learning-based bioinformatics analysis, we developed predictive models and identified key factors influencing growth in IgE-FA children. The IgE-FA prediction model achieved an area under the curve (AUC) of 0.78 (95% CI: 0.708–0.848). Greater birthweight, a family history of allergies, and early-life antibiotic exposure were identified as risk factors for IgE-FA. Notably, early antibiotic exposure increased the risk of IgE-FA by 2.77 times and the risk of milk allergy by 2.56 times. Growth analysis, both overall and by subgroup, revealed that pre-treatment weight strongly correlates with post-treatment height, weight, and body mass index (BMI), offering new perspectives for predicting and monitoring outcomes in IgE-FA. Milk allergy mainly impacts weight catch-up, whereas egg allergy affects BMI. Controlled avoidance of allergenic foods supports growth recovery in affected children.</div></div><div><h3>Conclusion</h3><div>Growth in children with IgE-FA is often restricted, and achieving expected growth levels remains challenging even after treatment. Weight is a sensitive and accessible indicator for predicting IgE-FA and plays a key role in post-treatment growth catch-up. Early and personalized nutritional guidance, along with regular weight monitoring, is recommended for all children with food allergy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101088"},"PeriodicalIF":3.9,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence in allergy practice: Digital transformation and the future of clinical care","authors":"Sandra Nora González-Díaz MD, PhD ,&nbsp;Mário Morais-Almeida MD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Carlos Macouzet-Sánchez MD, PhD ,&nbsp;Yeyetsy G. Ordóñez-Azuara MD, PhD ,&nbsp;José Camarena-Galván MD ,&nbsp;Jesús Marcelo Alanís-Alvarez MD","doi":"10.1016/j.waojou.2025.101078","DOIUrl":"10.1016/j.waojou.2025.101078","url":null,"abstract":"<div><div>Bioethics involves the analysis of human behavior in the life and health sciences, grounded in moral values and ethical principles. Its integration into the education and training of healthcare professionals is essential for addressing complex medical dilemmas, while also fostering behaviors that strengthen the doctor-patient relationship. The rapid advancement of technology, particularly artificial intelligence (AI), is transforming medical specialties and reshaping patient care. In the field of allergy and immunology, AI offers promising applications such as enhanced patient education, symptom tracking, personalized treatment planning, and improved clinical decision-making. However, its implementation raises significant ethical concerns. There is a risk of diminishing clinical reasoning skills due to excessive reliance on AI, as well as challenges related to data privacy, informed consent, and algorithmic transparency. These issues pose new bioethical dilemmas regarding patient autonomy and the humanization of care. This review explores the integration of AI in allergy practice, emphasizing its ethical implications and its potential impact on the doctor-patient relationship. Balancing technological innovation with core bioethical principles—non-maleficence, beneficence, autonomy, and justice—is critical for advancing patient-centered care in a digital era.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101078"},"PeriodicalIF":3.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Profile of mild/moderate asthma patients: Baseline data from the MANI cohort","authors":"Giovanna Elisiana Carpagnano PhD ,&nbsp;Matteo Bonini PhD ,&nbsp;Manuela Latorre PhD ,&nbsp;Eleonora Nucera MD ,&nbsp;Irene Prediletto PhD ,&nbsp;Francesca Puggioni MD ,&nbsp;Giulia Scioscia PhD ,&nbsp;Pierachille Santus PhD ,&nbsp;Giovanni Sotgiu PhD ,&nbsp;Francesco Blasi PhD ,&nbsp;Giorgio Walter Canonica MD ,&nbsp;Pierluigi Paggiaro MD ,&nbsp;Arianna Aruanno PhD ,&nbsp;Ilaria Baiardini PhD ,&nbsp;Diego Bagnasco PhD ,&nbsp;Benedetta Bondi MD ,&nbsp;Giulia Candeliere MD ,&nbsp;Francesca Cefaloni MD ,&nbsp;Gabriele Fontanili MD ,&nbsp;Laura Melissari MD ,&nbsp;Fulvio Braido MD","doi":"10.1016/j.waojou.2025.101082","DOIUrl":"10.1016/j.waojou.2025.101082","url":null,"abstract":"<div><div>Although 90% of asthmatic patients suffer from mild and moderate disease, little is known about the burden on health status and quality of life, the long-term trajectory of disease severity, and the socio-economic impact. The Mild Moderated Asthma Network of Italy (MANI) is a real-world, cross-sectional, prospective, observational cohort study designed to explore these issues. Here we aimed to provide an identikit of asthmatic patients receiving treatment according to GINA steps 1–4, and enrolled in the centers of excellence participating in the MANI. Among 679 analyzed patients, 63% were female, and the mean age was 50 ± 16 years. Asthma was mild in 15.8% of patients (GINA steps 1–2) and moderate in 84.2% (GINA steps 3–4). The mean age of asthma diagnosis was 34.3 ± 17.7 years, 50% of patients were suffering from allergic rhinitis, and 13% from nasal polyposis. Mean FEV1% was 91.4 ± 19.4%, predicted with a FEV1/FVC ratio of 74.7 ± 11.9. The mean asthma control test value was 21.2 ± 3.73, and AQLQ score was 5.74 ± 1.07. Among the included patients, 17.2% had at least one asthma exacerbation in the previous year, with 14.2% requiring systemic steroids; 6.2% were referred to an emergency room in the year prior to enrollment; 2.2% required an asthma-related hospitalization; and 0.6% had been admitted to an Intensive Care Unit (ICU). Unscheduled visits were necessary for 3.8% of patients, 6.5% reported ≥5 lost work days due to asthma, and 11.5% declared ≥10 lost days of spare time. About 70% of patients were receiving treatment according to GINA Track 1. Uncontrolled cases constituted 16.7% of patients treated according to GINA steps 1–2, and 26.3% of patients treated according to GINA steps 3-4 were uncontrolled. Compared to patients with mild asthma, those with moderate asthma had more impaired lung function (FEV1% 88.5 ± 18.4 vs 94.4 ± 17.9, p = 0.05; FEV1/FVC 73.0 ± 9.76 vs 79.6 ± 9.56, p &gt; 0.001), exhibited greater need for systemic corticosteroids for treating exacerbations (13.8% vs 2.3%, p = 0.032), and showed greater adherence to therapy (TAI score 50.0 ± 5.66 vs 45.7 ± 8.42, p &lt; 0.001). Overall, mild/moderate asthma exhibited a substantial clinical and care impact. Patients treated with GINA steps 3–4 constituted the vast majority of patients attending specialist centers. A quarter of these patients were uncontrolled, and therefore need re-evaluation or treatment upgrade. Expanding recruitment of the MANI study will allow further phenotyping of these patients.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101082"},"PeriodicalIF":3.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 2 Inflammatory Syndrome: Atopic and non-atopic endotypes","authors":"Pedro Giavina-Bianchi MD, PhD ,&nbsp;Rosana Camara Agondi MD, PhD ,&nbsp;Marcelo Vivolo Aun MD, PhD ,&nbsp;Jorge Kalil MD, PhD","doi":"10.1016/j.waojou.2025.101080","DOIUrl":"10.1016/j.waojou.2025.101080","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101080"},"PeriodicalIF":3.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How accurate are ChatGPT-4 responses in chronic urticaria? A critical analysis with information quality metrics","authors":"Ivan Cherrez-Ojeda Ph.D.(c) ,&nbsp;Marco Faytong-Haro Ph.D.(c) ,&nbsp;Patricio Alvarez-Muñoz Ph.D. ,&nbsp;José Ignacio Larco MD ,&nbsp;Erika de Arruda Chaves MD ,&nbsp;Isabel Rojo MD ,&nbsp;Carol Vivian Moncayo MD ,&nbsp;German D. Ramon MD ,&nbsp;Gabriela Rodas-Valero MD ,&nbsp;Emek Kocatürk MD ,&nbsp;Giselle S. Mosnaim MD ,&nbsp;Karla Robles-Velasco MD","doi":"10.1016/j.waojou.2025.101071","DOIUrl":"10.1016/j.waojou.2025.101071","url":null,"abstract":"<div><h3>Background</h3><div>The increasing use of artificial intelligence (AI) in healthcare, especially in delivering medical information, prompts concerns over the reliability and accuracy of AI-generated responses. This study evaluates the quality, reliability, and readability of ChatGPT-4 responses for chronic urticaria (CU) care, considering the potential implications of inaccurate medical information.</div></div><div><h3>Objective</h3><div>The goal of the study was to assess the quality, reliability, and readability of ChatGPT-4 responses to inquiries on CU management in accordance with international guidelines, utilizing validated metrics to evaluate the effectiveness of ChatGPT-4 as a resource for medical information acquisition.</div></div><div><h3>Methods</h3><div>Twenty-four questions were derived from the EAACI/GA²LEN/EuroGuiDerm/APAAACI recommendations and utilized as prompts for ChatGPT-4 to obtain responses in individual chats for each question. The inquiries were categorized into 3 groups: A.) Classification and Diagnosis, B.) Assessment and Monitoring, and C.) Treatment and Management Recommendations. The responses were separately evaluated by allergy specialists utilizing the DISCERN instrument for quality assessment, Journal of the American Medical Association (JAMA) benchmark criteria for reliability evaluation, and Flesch scores for readability analysis. The scores were further examined by median calculations and Intraclass Correlation Coefficient assessments.</div></div><div><h3>Results</h3><div>Categories A and C exhibited insufficient reliability according to JAMA, with median scores of 1 and 0, respectively. Category B exhibited a low reliability score (median 2, interquartile range 2). The information quality from category C questions was satisfactory (median 51.5, IQR 12.5). All 3 groups exhibited confusing readability levels according to the Flesch assessment.</div></div><div><h3>Limitations</h3><div>The study's limitations encompass the emphasis on CU, possible bias in question selection, the use of particular instruments such as DISCERN, JAMA, and Flesch, as well as reliance on expert opinion for assessment.</div></div><div><h3>Conclusion</h3><div>ChatGPT-4 demonstrates potential for producing medical content; nonetheless, its reliability is shaky underscoring the necessity for caution and confirmation when employing AI-generated medical information, especially in the management of CU.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101071"},"PeriodicalIF":3.9,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning-based model for acute asthma exacerbation detection using routine blood parameters","authors":"Youpeng Chen ,&nbsp;Junquan Sun ,&nbsp;Yabang Chen ,&nbsp;Enzhong Li ,&nbsp;Jiancai Lu ,&nbsp;Huanhua Tang ,&nbsp;Yifei Xie ,&nbsp;Jiana Zhang ,&nbsp;Lesi Peng ,&nbsp;Haojie Wu ,&nbsp;Zhangkai J. Cheng ,&nbsp;Baoqing Sun","doi":"10.1016/j.waojou.2025.101074","DOIUrl":"10.1016/j.waojou.2025.101074","url":null,"abstract":"<div><h3>Background</h3><div>Acute asthma exacerbations (AAEs) are a leading cause of asthma-related morbidity and mortality, especially in resource-limited settings where pulmonary function tests are unavailable or when patients are unable to cooperate with testing. This study aimed to develop and validate a diagnostic model for AAE using routine blood parameters through machine learning techniques.</div></div><div><h3>Methods</h3><div>We developed a machine learning-based diagnostic model using routine blood test parameters. Data from 23,013 asthma patients treated at the First Affiliated Hospital of Guangzhou Medical University were analyzed. Significant variables were identified through logistic regression, and 12 machine learning algorithms were used to construct diagnostic models, which were evaluated using Receiver Operating Characteristic (ROC) analysis, calibration, and Decision Curve Analysis (DCA).</div></div><div><h3>Results</h3><div>The Generalized Linear Model Boosting combined with Random Forest (glmBoost + RF) algorithm using 14 variables achieved comparable performance (Area Under the Curve [AUC] = 0.981) to the more complex Least Absolute Shrinkage and Selection Operator combined with Random Forest (Lasso + RF) algorithm using 25 variables (AUC = 0.985). Both models demonstrated excellent calibration and consistent performance across different demographic subgroups. DCA confirmed superior clinical utility compared to conventional strategies.</div></div><div><h3>Conclusions</h3><div>This machine learning model provides an efficient and practical tool for detecting AAE using routine blood parameters, offering potential value in clinical practice, especially in resource-limited settings.</div></div><div><h3>Clinical trial number</h3><div>Not applicable.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 7","pages":"Article 101074"},"PeriodicalIF":3.9,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}